Oral Session 2-14B Gene-modified T Cell Therapy

[OS2-14B-3] The manufacturing process of CD19 CAR-T in r/r B-cell lymphoma - the experience of a single center

Ken Ohmine^1,2, Ryosuke Uchibori², Kento Umino¹, Ikuei Nukaya⁴, Daisuke Tomura⁴, Hirotomo Nakashima¹, Takashi Ikeda¹, Yumiko Toda¹, Shinichiro Kawaguchi¹, Shoko Ito¹, Daisuke Minakata¹, Hirofumi Nakano¹, Shinichi Ochi¹, Takashi Nagayama¹, Kiyomi Mashima¹, Ryoko Yamasaki¹, Kaoru Morita¹, Masahiro Ashizawa¹, Kaoru Hatano¹, Masuzu Ueda¹, Kazuya Sato¹, Iekuni Oh¹, Shinichiro Fujiwara¹, Kiyoshi Okazuka⁵, Kazuo Muroi³, Junichi Mineno⁴, Yoshinobu Kanda¹, Keiya Ozawa² (1.Div. of Hematol, Jichi Medical Univ., Tochigi, Japan, 2.Immuno-Gene and Cell Therapy (Takara Bio), Jichi Medical Univ., 3.Div. of Cell Transplantation and Transfusion, Jichi Medical Univ. Hosp., 4.Takara Bio Inc., Kusatsu, Japan, 5.Japanese Red Cross Medical Center, Tokyo, Japan)